MedPath

Effect of Ocimum basilicum in anxiety

Phase 2
Recruiting
Conditions
Depression, anxiety.
Major depressive disorder, single episode
Registration Number
IRCT20230318057752N1
Lead Sponsor
Fasa University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Men and women between 18 and 65 years old
People with major depressive disorder based on DSM 5 criteria
Obtaining a minimum score of 18 in the Hamilton Anxiety Questionnaire
Not taking any new anti-anxiety medication in the last 1 month
Not suffering from significant internal diseases such as heart and lung failure, cancer, vascular disease, rheumatological disease, history of seizures and hypothyroidism, etc.
Not using anticoagulant or anti-platelet drugs such as warfarin, heparin, aspirin, etc.
No drug and alcohol addiction

Exclusion Criteria

Any allergy to Ocimum basilicum and its products
Pregnancy or breastfeeding
Hypersensitivity to specific serotonin re-uptake inhibitor drugs
Patients who will not have proper follow-up

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Depression score in Beck questionnaire. Timepoint: Before starting the study and 4 weeks after taking the drug. Method of measurement: Based on the Beck Depression Questionnaire.;Anxiety score in Hamilton questionnaire. Timepoint: Before starting the study and 4 weeks after taking the drug. Method of measurement: Based on Hamilton anxiety questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath